EFFECT OF TACROLIMUS EXPOSURE ON EVEROLIMUS-BASED IMMUNOSUPPRESSION IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: A 24-MONTH ANALYSIS FROM TRANSFORM STUDY

被引：0
|
作者：
Citterio, Franco [1 ]
Peddi, V. Ram [2 ]
Qazi, Yasir [3 ]
Kim, Dean [4 ]
Vincenti, Flavio [5 ]
Berger, Stefan [6 ]
Sommerer, Claudia [7 ]
Gawai, Apurva [8 ]
Hernandez-Gutierrez, Maria-Pilar [9 ]
Bernhardt, Peter [9 ]
Oberbauer, Rainer [10 ]
机构：
[1] Sacred Heart Catholic Univ, Gemelli Univ Hosp Fdn, IRCCS, Rome, Italy
[2] Calif Pacific Med Ctr, San Francisco, CA USA
[3] Univ Southern Calif, Los Angeles, CA 90007 USA
[4] Henry Ford Hosp, Detroit, MI 48202 USA
[5] Univ Calif San Francisco, San Francisco, CA 94143 USA
[6] Univ Med Ctr Groningen, Groningen, Netherlands
[7] Univ Hosp, Renal Clin Heidelberg, Heidelberg, Germany
[8] Novartis Healthcare Pvt Ltd, Mumbai, Maharashtra, India
[9] Novartis Pharma AG, Basel, Switzerland
[10] Med Univ Vienna, Univ Clin Internal Med 3, Vienna, Austria
来源：
TRANSPLANT INTERNATIONAL | 2021年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
POS129
引用
收藏
页码：254 / 255
页数：2
相关论文
共 50 条
  • [41] EVEROLIMUS WITH LOW OR VERY LOW EXPOSURE OF TACROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTS: THE ASSET STUDY
    Vitko, Stefan
    Hene, Ronald
    Langer, Robert
    Christiaans, Maarten
    Tedesco, Helio
    Ciechanowski, Kazimierz
    Cassuto, Elizabeth
    Rostaing, Lionel
    Vilatoba, Mario
    Pascual, Julio
    TRANSPLANT INTERNATIONAL, 2009, 22 : 53 - 53
  • [42] Effect of Everolimus Based Immunosuppression on De Novo Heart Transplant Recipients-24 Months Efficacy and Safety Results from A2310 Study
    Kobashigawa, J.
    Pauly, D.
    Kfoury, A.
    Ross, H.
    Wang, S. -S.
    Cantin, B.
    van Bakel, A.
    Starling, R.
    Hirt, S.
    Dong, G.
    Panis, C.
    Lopez, P.
    Eisen, H.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 67 - 68
  • [43] LIPID ABNORMALITIES AND CARDIOVASCULAR EVENTS IN RENAL TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS WITH REDUCED-EXPOSURE CALCINEURIN INHIBITOR REGIMEN: 24-MONTH ANALYSIS FROM TRANSFORM STUDY
    Sommerer, Claudia
    Legendre, Christophe
    Citterio, Franco
    Watarai, Yoshihiko
    Oberbauer, Rainer
    Basic-Jukic, Nikolina
    Garcia, Valter Duro
    Peddi, V. Ram
    Hernandez-Gutierrez, Maria-Pilar
    Narvekar, Prachiti
    Bernhardt, Peter
    Chadban, Steve
    TRANSPLANT INTERNATIONAL, 2019, 32 : 71 - 71
  • [44] CORRELATION OF EVEROLIMUS EXPOSURE WITH EFFICACY AND SAFETY OUTCOMES IN RENAL TRANSPLANT RECIPIENTS: 24-MONTH UPDATE
    Carmellini, M.
    Yaqoob, M.
    Pattison, J.
    Riad, H.
    Wang, Z.
    Cornu-Artis, C.
    Silva, H. Tedesco
    TRANSPLANT INTERNATIONAL, 2011, 24 : 248 - 248
  • [45] Efficacy and Safety Outcomes with De Novo Use of Everolimus-Based Regimen in Renal Transplant Recipients with Delayed Graft Function from the TRANSFORM Study.
    Chadban, S.
    Oppenheimer, F.
    Citterio, F.
    Witzke, O.
    Garcia, V. D.
    Gutierrez-Dalmau, A.
    Narvekar, P.
    Gutierrez, M. P. Hernandez
    Bernhardt, P.
    Wiseman, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 357 - 358
  • [46] Everolimus Facilitated Reduction of Tacrolimus in De Novo Liver Transplant Recipients: 12-24 Month Data from North America.
    Chapman, W.
    Brown, R., Jr.
    Sudan, D.
    Chavin, K.
    Koneru, B.
    Huang, M.
    Junge, G.
    Hexham, J.
    Dong, G.
    Wiland, A.
    Fung, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 506 - 507
  • [47] Everolimus facilitated reduction of tacrolimus in de novo liver transplant recipients (LTxR): 12-24 month data from North America
    Chapman, W. C.
    Brown, R. S., Jr.
    Sudan, D.
    Chavin, K. D.
    Koneru, B.
    Huang, M. A.
    Junge, G.
    Hexham, J. M.
    Dong, G.
    Wiland, A.
    Patel, D.
    Fung, J.
    PHARMACOTHERAPY, 2013, 33 (10): : E237 - E238
  • [48] TRANSFORM STUDY TO EVALUATE THE EFFECT OF EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITORS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: BASELINE DATA
    Arns, W.
    Weithofer, P.
    Witzke, O.
    Habicht, A.
    Banas, B.
    Renders, L.
    Rath, T.
    Lehner, F.
    Bartels, M.
    Von der Giet, M.
    Sommerer, C.
    TRANSPLANT INTERNATIONAL, 2015, 28 : 25 - 25
  • [49] Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study
    Citterio, Franco
    Henry, Mitchell
    Kim, Dean Y.
    Kim, Myoung Soo
    Han, Duck-Jong
    Kenmochi, Takashi
    Mor, Eytan
    Tisone, Giuseppe
    Bernhardt, Peter
    Gutierrez, Maria Pilar Hernandez
    Watarai, Yoshihiko
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (10) : 1339 - 1348
  • [50] Efficacy and Safety Outcomes by Donor Type in De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from Transform
    Berger, S.
    Bakr, M.
    Bemelman, F.
    Danguilan, R.
    De Fijter, H.
    Han, D.
    Kim, M.
    Mor, E.
    Patel, A.
    Gutierrez, M. Hernandez
    Gawai, A.
    Watarai, Y.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 942 - 943
12345